| Dr Norman F Bradford, MD | |
|
112 N. Seventh Street, Chambersburg, PA 17201 | |
| (717) 267-7164 | |
| (717) 267-7414 |
| Full Name | Dr Norman F Bradford |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 39 Years |
| Location | 112 N. Seventh Street, Chambersburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518952555 | NPI | - | NPPES |
| 25-1716306 | Other | PA | FIRST HEALTH |
| 5969102 | Other | PA | AETNA NON-HMO |
| MD038978E | Other | PA | MEDICAL LICENSE |
| 25-1716306 | Other | PA | INTERGROUP |
| 273307 | Other | PA | UNISON |
| 120420418 | Other | PA | DEPT OF LABOR |
| 25-1716306 | Other | PA | SOUTH CENTRAL |
| 6906113 | Other | PA | AETNA HMO |
| G920-0122/85XWCU | Other | PA | CAREFIRST |
| 1717223 | Other | PA | HIGHMARK BLUE SHIELD |
| 25-1716306 | Other | PA | MULTIPLAN/PHCS |
| 1583301 | Other | PA | GATEWAY |
| 2183091 | Other | PA | MAMSI |
| 25-1716306 | Other | PA | INFORMED |
| 001522547 0006 | Medicaid | PA | |
| P00741672 | Other | PA | RAILROAD MEDICARE |
| 251716306 | Other | PA | HEALTH NET |
| 50085998 | Other | PA | CAPITAL BLUECROSS |
| 050514 | Other | PA | GROUP MEDICARE # |
| 25-1716306 | Other | PA | DEVON |
| PEARL | Other | PA | HEALTH AMERICA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | D38813 (Maryland) | Secondary |
| 207L00000X | Anesthesiology | MD038978E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Waynesboro Hospital | Waynesboro, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wellspan Medical Group | 1951213115 | 1946 |
News Archive
CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.
The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.
The slurred speech, poor coordination, and sedative effects of drinking too much alcohol may actually be caused by the breakdown of alcohol products produced in the brain, not in the liver as scientists currently think
The National Institute on Aging of the National Institutes of Health has awarded researchers at Washington University School of Medicine in St. Louis a five-year, $9.1 million grant to study resilience in older adults before and during the COVID-19 pandemic, as well as the pandemic's cognitive and emotional effects on older adults.
› Verified 7 days ago
| Entity Name | Summit Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306840814 PECOS PAC ID: 5496659484 Enrollment ID: O20031121000259 |
News Archive
CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.
The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.
The slurred speech, poor coordination, and sedative effects of drinking too much alcohol may actually be caused by the breakdown of alcohol products produced in the brain, not in the liver as scientists currently think
The National Institute on Aging of the National Institutes of Health has awarded researchers at Washington University School of Medicine in St. Louis a five-year, $9.1 million grant to study resilience in older adults before and during the COVID-19 pandemic, as well as the pandemic's cognitive and emotional effects on older adults.
› Verified 7 days ago
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.
The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.
The slurred speech, poor coordination, and sedative effects of drinking too much alcohol may actually be caused by the breakdown of alcohol products produced in the brain, not in the liver as scientists currently think
The National Institute on Aging of the National Institutes of Health has awarded researchers at Washington University School of Medicine in St. Louis a five-year, $9.1 million grant to study resilience in older adults before and during the COVID-19 pandemic, as well as the pandemic's cognitive and emotional effects on older adults.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Norman F Bradford, MD 785 5th Avenue, Suite 3, Chambersburg, PA 17201-4232 Ph: (717) 263-9555 | Dr Norman F Bradford, MD 112 N. Seventh Street, Chambersburg, PA 17201 Ph: (717) 267-7164 |
News Archive
CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.
The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.
The slurred speech, poor coordination, and sedative effects of drinking too much alcohol may actually be caused by the breakdown of alcohol products produced in the brain, not in the liver as scientists currently think
The National Institute on Aging of the National Institutes of Health has awarded researchers at Washington University School of Medicine in St. Louis a five-year, $9.1 million grant to study resilience in older adults before and during the COVID-19 pandemic, as well as the pandemic's cognitive and emotional effects on older adults.
› Verified 7 days ago
Dr. Kantilal C. Patel, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 112 North Seventh Street, Chambersburg, PA 17201 Phone: 717-267-3000 Fax: 717-217-4217 | |
Ali Yousufuddin, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 69 St Paul Dr Ste B, Chambersburg, PA 17201 Phone: 717-218-8800 Fax: 717-552-2196 | |
Timothy J Sempowski, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 112 N 7th St, Chambersburg, PA 17201 Phone: 717-267-7164 Fax: 717-267-7414 | |
Peter D Resnick, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 112 N 7th St, Chambersburg, PA 17201 Phone: 717-267-7164 Fax: 717-267-7414 | |
Bradley W. Heffner, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 112 N 7th St, Chambersburg, PA 17201 Phone: 717-267-7164 Fax: 717-267-7414 | |
Dr. Govindachetty Balaraman, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1418 Hearthside Dr, Chambersburg, PA 17201 Phone: 717-267-1405 | |
Meagan Horst, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 112 N 7th St, Chambersburg, PA 17201 Phone: 717-267-7164 |